EUCTR2022-001151-16-BG招募中1 期
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 850
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Rollover Participants
- •1. Completed 6 weeks of post-randomization treatment in Trial CVL-231-2001 or CVL-231-2002 and who, in the opinion of the investigator, could potentially benefit from treatment with emraclidine for schizophrenia.
- •2. Outpatient status at last day of treatment period (Day 45) of the preceding double-blind trial (CVL-231-2001 or CVL-231-2002) defined as follows:
- •Ability to be discharged from the hospital on Day 45 of Trial CVL-231-2001 or CVL-231-2002
- •Hospitalization for psychosocial reasons (eg, homelessness or need for shelter that is unrelated to the participant’s underlying psychiatric condition) will be considered outpatient status
- •Participants remaining in hospital at Day 45 of Trial CVL-231-2001 or CVL-231-2002 (for other than psychosocial reasons) will be permitted to enroll in Trial CVL-231-2003 at Day 45 of the double-blind trial if they are planned to be discharged from the hospital before the Week 1 visit of Trial CVL-231-2003
- •Participants not discharged by the Week 1 visit of Trial CVL-231-2003 must be withdrawn
- •3. Agree to comply with the following contraception requirements during the trial and for 7 days after the last dose of IMP:
- •Sexually active men must agree to use a condom during treatment and until the end of relevant systemic exposure in women of childbearing potential (ie, 7 days after the last dose of IMP)
- •Sexually active women of childbearing potential must use acceptable (at minimum) contraception as defined in Section 10.4.1.1 of the Protocol
- •In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.
- •4. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in Section 10.1.3. of the Protocol
- •5. Ability, in the opinion of the investigator, to understand the nature of the trial, participate in trial visits, and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, outcomes measures, and other trial procedures.
- •De Novo Participants
- •6. Male and female participants, ages 18 to 65 years, inclusive, at the time of signing the ICF.
- •7. Primary diagnosis of schizophrenia per DSM-5, as confirmed by the MINI for Psychotic Disorders version 7.0.2.
- •8. Participants who have been stable on antipsychotic medication for at least one 3-month period in the year prior to screening (received the same medication or group of medications for at least 3 consecutive months in the prior year and demonstrated stability of symptoms on the antipsychotic medication).
- •9. Outpatient status at the time of signing the ICF. Hospitalization for psychosocial reasons (eg, homelessness or need for shelter that is unrelated to the participant’s underlying psychiatric condition) will be considered outpatient status. Participants may be hospitalized for not more than 14 days during the conversion to emraclidine with the approval of the medical monitor but must be discharged from the hospital before the Week 1 visit.
- •10. Scores as follows (normal to mild symptoms) at the time of signing the ICF and Baseline (Day 1):
- •All individual items of the SAS <2
- •All individual items (Items 1-7) of the AIMS <2
- •Clinical global assessment item of the BARS <3
- •11. Willing to discontinue all prohibited medications to meet protocol-required washouts prior to and during the trial period.
- •12. Resides in a stable living environment as demonstrated by the
排除标准
- •Rollover Participants
- •1.Participants who had a clinically significant medical, surgical, psychiatric, or laboratory/ECG abnormality during conduct of the previous double-blind trial that could compromise either participant safety or the results of the trial
- •2.Yes” responses for suicidal ideation item 4 and 5 or any of the suicidal behavior items on the C-SSRS at any time point during the prior double-blind trial
- •3.Likely to require prohibited concomitant therapy during the trial
- •4.Positive pregnancy test result prior to receiving IMP
- •5.Orthostatic hypotension or Systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg at the Week 6 Visit (Day 45) of preceding double-blind trial
- •6.Considering or scheduled to undergo any surgical procedure during the trial
- •De Novo Participants
- •7.Current DSM-5 diagnosis other than schizophrenia
- •8. Schizophrenia considered resistant/refractory to antipsychotic treatment by history or history of response to clozapine treatment only or failure to respond to clozapine treatment for schizophrenia
- •9.History of tardive dyskinesia or extrapyramidal symptoms that required medication within 6 months prior to signing the ICF
- •10.Current or past history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine, malignancy, hematological, immunological, neurological, or psychiatric disease that could compromise either participant safety or the results of the trial
- •11.Current or past history of significant cardiovascular disease
- •12.Active central nervous system infection, demyelinating disease, degenerative neurological disease, intellectual disability, brain tumor, prior hospitalization for severe head trauma, seizures, or any central nervous system disease deemed to be progressive during the course of the trial that may confound the interpretation of the trial results
- •13.Diagnosis of moderate to severe substance or alcohol-use disorder as per DSM-5 criteria within 12 months prior to signing the ICF
- •14.Yes” responses for suicidal ideation item 4 and 5 or any of the suicidal behavior items on the C-SSRS (within the past 6 months)
- •15.Any condition or surgery that could possibly affect drug absorption
- •16.This criterion has been removed effective protocol version 3.0
- •17.Use of prohibited medications prior to randomization within the required wash-out period or likely to require prohibited concomitant therapy during the trial
- •18.Transcranial magnetic stimulation or electroconvulsive therapy within 90 days of signing the ICF
- •19.Positive result for HIV antibody, HBV surface antigen, or HCV antibody with detectable viral RNA levels at Screening
- •20.Positive drug screen or a positive test for alcohol
- •21. AST or ALT =2 × ULN or total bilirubin >1.5 × ULN at the Screening Visit, confirmed by a single repeat measurement
- •22.Positive pregnancy test result prior to receiving IMP
- •23.12-lead ECG demonstrating any of the following at the Screening Visit and at Baseline:
- •QTcF interval >450 ms
- •QRS interval >120 ms (unless right bundle branch block)
- •PR interval >200 ms
- •LVH with ST depressions and/or T wave inversions in leads with relatively tall R waves
- •Type 2 second-degree or third-degree atrioventricular block
- •Heart rate <45 bpm or >100 bpm
- •Abnormal ECG changes
- •Abnormal heart rhythm
- •24.Orthostatic hypotension or Systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg at the Screening Visit and/or at Baseline
- •25.Any other abnormal safety f
研究者
相似试验
进行中（未招募）
1 期
A Trial of 10, 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaEUCTR2022-001151-16-HUCerevel Therapeutics, LLC850
招募中
1 期
A 52-week, Open-label Trial of CVL-231 in Adult Participants With SchizophreniaMedDRA version: 20.0Level: HLGTClassification code: 10039628Term: Schizophrenia and other psychotic disorders Class: 10037175SchizophreniaCTIS2024-511441-19-00850
进行中（未招募）
2 期
A trial to learn about the long-term safety and efficacy of a study drug (STAR-0215) in adult patients with hereditary angioedemaHereditary angioedema (HAE)Circulatory SystemISRCTN17914189Astria Therapeutics, Inc. (USA)56
进行中（未招募）
不适用
Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line treatment with Cetuximab + FOLFIRI in patients with metastatic colorectal cancer KRAS wild-type – TAGUS Study - TAGUS StudyEUCTR2008-008282-36-PTGrupo de Investigação do Cancro Digestivo
撤回
2 期
A randomized open-label Phase 2a study to assess the pharmacokinetics and pharmacodynamic parameters of PXL770 after 12 weeks of treatment in male subjects with adrenomyeloneuropathy (AMN)AdrenoleukodystrophyNL-OMON51808Poxel S.A.14